title: [Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].
abstract: OBJECTIVE
  The epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) shows favorable antitumor activity against chemorefractory non-small cell lung cancer (NSCLC). However, patients with advanced NSCLC have limited treatment options available if they are refractory to EGFR-TKI. To study the influence of the retreatment EGFR-TKI after failure of first-line TKI, we carried out this retrospective study.
  
  
  METHODS
  Total 71 patients were analyzed who experienced treatment failure from their initial use of EGFR-TKI. After a period of time, they were retreated with TKI as tumor progression was observed.
  
  
  RESULTS
  Of the 71 patients who received retreatment TKI, it was observed in 7% in partial response (PR), 36.6% in stable disease (SD), 56.3% in progressive disease (PD). Disease control rate (DCR) was 43.7%. Twenty-six (36.6%) patients were well controlled by retreatment with TKI monotherapy for not less than 3 months. Five (7.0%) patients had partial response. Exon 21 mutation, PFS not less than 6 months during initial treatment TKI, and the interval not less than 3 months between initial treatment, and retreatment with TKI was associated with a good progression free survival based on univariate COX analysis (P=0.034; P=0.013; P=0.046).
  
  
  CONCLUSIONS
  It has been shown the possibility that retreatment with TKI might be useful when (1) Exon 21 has active mutation, (2) initial treatment shows a favorable PFS (≥ 6 months), and (3) there has been a period of time (≥3 months) following the termination of the initial TKI treatment.
authors.affiliation: Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing University Oncology College, Beijing, China.
authors.forename: Tongtong
authors.initials: T
authors.lastname: An
authors.forename: Zhen
authors.initials: Z
authors.lastname: Huang
authors.forename: Yuyan
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhijie
authors.initials: Z
authors.lastname: Wang
authors.forename: Hua
authors.initials: H
authors.lastname: Bai
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019233:Retreatment; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors